ABSTRACT
Objective: To investigate the incidence, clinical, biochemical and gene mutation characteristics of short chain acyl-coenzyme A dehydrogenase deficiency (SCADD). Method: From January, 2009 to October, 2015, a retrospective analysis of the urine organic acids and acyl-coenzyme A dehydrogenase (ACADS) gene mutation characteristics of patients diagnosed as SCADD by newborn screening using tandem mass spectrometry in Department of Genetics and Metabolism (Newborn screening Center of Zhejiang Province), Children's Hospital, Zhejiang University School of Medicine. Dietary guidance, life management and supplementation of L-carnitine were conducted, and growth and intelligence development were observed during follow-up among the SCADD patients. Result: A total of 1 430 024 neonates, seventeen cases were diagnosed with SCADD with an incidence of 1/84 117. All patients had no clinical symptoms, and intelligence and physical development were normal. Blood butylacyl-carnitine (C4) levels and the ratios increased, C4 0.713.14 µmol/L(reference value 0.03-0.48 µmol/L), C4/C2 0.07-0.23(reference value 0.01-0.04), C4/C3 0.65-2.04(reference value 0.05-0.39). Thirteen with increased urinary ethyl malonic acid (9.30-90.99 mg/g creatinine (reference value 0-6.20 mg/g creatinine )), one patient was accompanied by increased methyl succinic acid (12.33 mg/g creatinine(reference value 0-6.40 mg/g creatinine)), one subject with increased acetylglycine (3.52 mg/g creatinine(reference value 0-0.70 mg/g creatinine)). A total of 13 known mutations were detected in the ACADS gene, 1 homozygous mutation (c.1031A>G), the others are compound heterozygous mutations. One frameshift mutation (c.508_509delGC) and 12 missense mutations were detected. Common mutation were c. 1031A>G(35.3%), c. 164C>T(20.6%) and c. 991G>A(11.8%). SCADD in newborn screening program had no clinical symptoms and normal growth development after 8-42 months follow-up. Conclusion: Cases with SCADD had no clinical symptoms with an incidence of 1/84117. The c. 164C>T and c. 1031A>G may be the common mutations.
Subject(s)
Acyl-CoA Dehydrogenase/deficiency , Amino Acid Metabolism, Inborn Errors/genetics , Lipid Metabolism, Inborn Errors/genetics , Neonatal Screening/methods , Acyl-CoA Dehydrogenase/blood , Acyl-CoA Dehydrogenase/genetics , Amino Acid Metabolism, Inborn Errors/blood , Amino Acid Metabolism, Inborn Errors/ethnology , Carnitine/blood , Child , China/epidemiology , Homozygote , Humans , Incidence , Infant, Newborn , Lipid Metabolism, Inborn Errors/blood , Lipid Metabolism, Inborn Errors/ethnology , Male , Mutation , Retrospective Studies , Tandem Mass SpectrometryABSTRACT
Microbial transformation of fraxinellone (1) by Aspergillus niger (AS 3.421) has been carried out. Two converted products, dasycarpol (2) and a new compound fraxinigerllone (3) were obtained. Their structures have been identified on the basis of spectroscopic methods. Dasycarpol shows moderate inhibitory activity on lung cancer cell line A549.